-
1.发明公开
公开(公告)号：EP1534344A2
公开(公告)日：2005-06-01
申请号：EP03762001.0
申请日：2003-06-25
IPC分类号： A61K48/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K39/292 , A61K2039/5254 , A61K2039/5256 , A61K2039/5258 , A61K2039/542 , C07K2319/00 , C12N7/00 , C12N2720/10023 , C12N2720/10043 , C12N2720/10061 , C12N2720/10062 , C12N2720/12023 , C12N2730/10122 , C12N2730/10134 , C12N2740/16034 , C12N2740/16061 , C12N2770/22022 , C12N2770/22023 , C12N2770/22043 , C12N2770/32043 , C12N2810/854
摘要： The present invention relates to the display of antigenic or allergenic components along with a tissue-targeting component on viruses or virus-like particles. Capsid protein genes are recombinantly modified to contain the specified components, then expressed within a host organism, such as yeasts, bacteria, or algae, and allowed to spontaneously form active virus particles or virus-like particles. The recombinant complexes (virus or virus-like particle) can then be purified or used in situ as a therapeutic tool for disease or allergy prevention. The expression of multivalent and multifunctional components to increase the immunogenicity of the recombinant complexes, especially on oral administration, is provided.
-
2.发明公开
公开(公告)号：EP1534344A4
公开(公告)日：2008-05-28
申请号：EP03762001
申请日：2003-06-25
发明人： ALLNUTT F C THOMAS , KYLE DAVID J
IPC分类号： A61K39/00 , A61K39/21 , A61K39/29 , C07K14/01 , C07K14/08 , C07K14/16 , C12N7/00 , C12N7/04 , A61K48/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K39/292 , A61K2039/5254 , A61K2039/5256 , A61K2039/5258 , A61K2039/542 , C07K2319/00 , C12N7/00 , C12N2720/10023 , C12N2720/10043 , C12N2720/10061 , C12N2720/10062 , C12N2720/12023 , C12N2730/10122 , C12N2730/10134 , C12N2740/16034 , C12N2740/16061 , C12N2770/22022 , C12N2770/22023 , C12N2770/22043 , C12N2770/32043 , C12N2810/854
-
公开(公告)号：EP3212224A1
公开(公告)日：2017-09-06
申请号：EP15797871.9
申请日：2015-10-28
发明人： GEALL, Andrew , ALTER, Galit , SUSCOVICH, Todd
IPC分类号： A61K39/00 , C12N15/00 , C07K16/10 , A61K39/145 , C07K16/00
CPC分类号： C07K16/1018 , A61K39/12 , A61K39/145 , A61K2039/515 , C07K16/00 , C07K16/10 , C07K2317/10 , C12N15/00 , C12N2760/16211 , C12N2770/32043 , C12N2770/36143 , C12N2830/20
摘要： The present invention relates to methods exogenous nucleic acid molecules, such as RNA, that encode an antibody or antigen-binding fragment of an antibody, and optionally encode a cellular modulation factor and/or a potentiation factor. The cellular modulation factor is a factor that results in increased expression of the antibody and/or antigen-binding fragment. The potentiation factor is a factor that provides desired antibody effector or other properties. The exogenous nucleic acid molecules can be DNA or RNA, as mRNA (including self-replication RNA and non-self-replicating RNA). The invention also relates method for administering the exogenous nucleic acid molecules to a subject to achieve production of the encoded antibody or antigen-binding fragment in the subject to provide, for example, prophylactic or therapeutic passive immunity.
摘要翻译： 本发明涉及编码抗体或抗体的抗原结合片段的外源性核酸分子如RNA的方法，并且任选编码细胞调节因子和/或增强因子。 细胞调节因子是导致抗体和/或抗原结合片段表达增加的因子。 增强因子是提供所需抗体效应物或其他性质的因子。 外源核酸分子可以是DNA或RNA，如mRNA（包括自我复制RNA和非自我复制RNA）。 本发明还涉及将外源性核酸分子施用于受试者以实现受试者中编码的抗体或抗原结合片段的产生以提供例如预防性或治疗性被动免疫的方法。
-
公开(公告)号：EP2987858A4
公开(公告)日：2016-12-21
申请号：EP14786082
申请日：2014-04-17
发明人： TANI KENZABURO , MIYAMOTO SHOHEI , INOUE HIROYUKI , SAGARA MIYAKO
CPC分类号： A61K35/768 , A61K35/76 , C12N7/00 , C12N15/86 , C12N2770/32032 , C12N2770/32043 , C12N2770/32321 , C12N2770/32332 , C12N2770/32343
摘要： A modified coxsackievirus showing improved safety and/or aggressiveness to be used for oncolytic virotherapy is provided. A modified coxsackievirus showing tissue-specific suppression of proliferation and comprising a mutated genome consisting of the genome of coxsackievirus B3 wild-type (CVB3-WT) inserted with at least one polynucleotide consisting of a target sequence of tissue-specific microRNA (miRNA) is provided. The mutated genome is preferably further inserted with the region encoding GM-CSF in an expressible form.
-
公开(公告)号：EP2987858A1
公开(公告)日：2016-02-24
申请号：EP14786082.9
申请日：2014-04-17
CPC分类号： A61K35/768 , A61K35/76 , C12N7/00 , C12N15/86 , C12N2770/32032 , C12N2770/32043 , C12N2770/32321 , C12N2770/32332 , C12N2770/32343 , Y02A50/465
摘要： A modified coxsackievirus showing improved safety and/or aggressiveness to be used for oncolytic virotherapy is provided. A modified coxsackievirus showing tissue-specific suppression of proliferation and comprising a mutated genome consisting of the genome of coxsackievirus B3 wild-type (CVB3-WT) inserted with at least one polynucleotide consisting of a target sequence of tissue-specific microRNA (miRNA) is provided. The mutated genome is preferably further inserted with the region encoding GM-CSF in an expressible form.
摘要翻译： 提供了改进的用于溶瘤病毒疗法的安全性和/或侵蚀性的改良柯萨奇病毒。 显示组织特异性抑制增殖的修饰的柯萨奇病毒包含插入有至少一种由组织特异性微小RNA（miRNA）的靶序列组成的多核苷酸的柯萨奇病毒B3野生型（CVB3-WT）的基因组的突变基因组， 提供。 突变的基因组优选进一步插入编码GM-CSF的区域以可表达的形式。
-
公开(公告)号：EP2978850A1
公开(公告)日：2016-02-03
申请号：EP14714776.3
申请日：2014-03-24
发明人： SIMMONDS, Peter
IPC分类号： C12N15/86
CPC分类号： C12N15/86 , C12N2760/16143 , C12N2770/32043
摘要： The present invention relates to methods and compositions for enhancing expression from RNA expression vectors. The invention is based upon the observation that reducing the frequency of the dinucleotides CpG and UpA has a significant effect on expression from such vectors. Aspects of the invention include, amongst others, synthetic RNA vectors, virions, cells, methods of producing vaccines and methods of treatment or immunisation.
摘要翻译： 本发明涉及用于增强RNA表达载体表达的方法和组合物。 本发明基于以下观察：降低二核苷酸CpG和UpA的频率对来自这些载体的表达具有显着影响。 本发明的方面包括合成RNA载体，病毒粒子，细胞，生产疫苗的方法和治疗或免疫方法。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.011 秒)
